产品

本公司产品仅供体外研究使用,不用于临床诊断

TNFAIP3 antibody

分类: 研究方向:
别称:A20 antibody, OTUD7C antibody, TNF alpha induced protein 3 antibody, TNFA1P2 antibody, TNFAIP3 antibody, Zinc finger protein A20 antibody
货号:FNab10029反应性:Human, Mouse
宿主:Rabbit验证实验:ELISA, WB, IHC
克隆性:polyclonal亚型:IgG
¥1500
规格:
货期: 三个工作日+顺丰快递时长
  • 产品介绍
产品名称
TNFAIP3 antibody
货号
FNab10029
规格
100μg
状态
liquid
纯化方法
Immunogen affinity purified
纯度
≥95% as determined by SDS-PAGE
克隆性
polyclonal
亚型
IgG
存储
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
免疫原信息
免疫原
tumor necrosis factor, alpha-induced protein 3
别称
A20 antibody, OTUD7C antibody, TNF alpha induced protein 3 antibody, TNFA1P2 antibody, TNFAIP3 antibody, Zinc finger protein A20 antibody
UniProt ID
P21580
分子量
90 kDa
验证实验
验证实验
ELISA, WB, IHC
建议稀释比例
WB: 1:500-1:2000; IHC: 1:50-1:500
验证图片
K562 cells were subjected to SDS PAGE followed by western blot with FNab10029(TNFAIP3 antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded human breast cancer using FNab10029(TNFAIP3 antibody) at dilution of 1:100
背景介绍
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors(TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF-or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor(TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM(CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase(IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'-and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.